Orthofix International

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Orthofix and SeaSpine post mixed Q4 results, eye synergies and growth

SeaSpine and Orthofix reported mixed Q4 performances but demonstrated overall revenue growth for the full year, with positive revenue guidance for 2023.
The merger synergies and product demand strengths are key highlights, while challenges in profitability and regulatory hurdles in Europe require attention.
Opportunities lie in integration efforts, cost efficiencies, and exploring new markets, indicating a strategic growth trajectory for the combined entity.
The upcoming Analyst Teach-In event and focus on operational planning underscore the commitment to transparency and strategic alignment post-merger.

Orthofix reports robust Q1 earnings, raises full-year revenue guidance

Orthofix International's Q1 2023 earnings call highlighted strong financial performance, strategic initiatives, and raised revenue guidance, underscoring growth prospects.
The company's focus on operational efficiency, product categories, and profitability signals a resilient business strategy amidst market challenges and competitive landscape.
With a robust financial foundation, Orthofix is well-positioned to navigate challenges, capitalize on growth opportunities, and drive sustainable value creation for shareholders.

Orthofix International reports robust Q2 earnings and growth outlook

Orthofix International delivered a strong Q2 performance, with notable revenue growth and positive outlook for 2023.
Efforts to integrate merged businesses are yielding results, with a focus on revenue enhancement and operational streamlining.
Challenges such as cash flow and supply chain disruptions are being addressed through strategic investments and operational improvements.
The company's focus on growth, efficiency, and strategic partnerships positions it well for future success and value creation.

Orthofix reports robust Q3 revenue growth, eyes profitability and stability

Orthofix International demonstrated strong revenue growth and market performance in Q3 2023, driven by successful product lines and strategic initiatives.
While facing challenges such as cash flow outflows and margin adjustments, the company remains focused on profitability and financial stability.
Opportunities lie in sustaining positive momentum, achieving cash flow positivity in 2024, and leveraging growth prospects through product innovation and market expansion.

Orthofix reports robust Q4 earnings, eyes growth in key segments

Orthofix International's Q4 2023 earnings call highlighted strong financial performance, strategic initiatives, and growth in key segments.
The company's focus on market share, distributor relationships, and portfolio enhancements positions it well for future success.
Despite challenges in a competitive landscape, Orthofix remains optimistic about growth opportunities and aims for continued innovation and collaboration.

Orthofix International reports robust Q1 earnings and raises 2024 guidance

Orthofix International (OFIX) delivered a strong Q1 2024 performance, focusing on growth, innovation, and operational efficiency. The company showcased revenue growth, margin expansion, and strategic priorities for the year. Challenges include sustaining growth in competitive markets and optimizing operational aspects, while opportunities lie in leveraging technology and talent for further growth.

Orthofix International reports strong Q2 performance and outlines growth strategies

Orthofix International's Q2 performance reflects solid revenue growth and margin expansion, supported by new product releases and operational efficiency.
While facing challenges in cash flow optimization, the company's strategic focus on innovation and synergies positions it well for future growth.
Opportunities in technology investment, cross-selling, and distribution enhancements offer avenues for Orthofix International to drive sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEWISVILLE, Texas--(BUSINESS WIRE)--The OrthoNext™ digital platform enables selection of device size and the optimal positioning for the patient's body prior to the surgical procedure.

Orthofix Announces FDA Clearance of the OrthoNext Digital Platform for the JuniOrtho Plating System

Strong sales of Orthofix's (OFIX) M6-C artificial disc and FITBONE lengthening nail drive its Q1 top line.

Orthofix's (OFIX) Q1 Earnings Top Estimates, 2021 View Up

Orthofix Medical's (OFIX) CEO Jon Serbousek on Q1 2021 Results - Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of 142.86% and 10.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Surpasses Q1 Earnings and Revenue Estimates

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended March 31, 2021. Net sales were $105.6 million, earnings per share (“EPS”) was $(0.30) and adjusted EPS was $0.17. “We are excited about the topline performance of the business during the first quarter, particularly as we continued to contend with the headwinds of the global pandemic and the added challenges of the recent severe winter weather-related disruption,” sa

Orthofix Reports First Quarter 2021 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix announces exclusive U.S. license for IGEA's bone and joint stimulation devices to expand the Company's Bone Growth Therapy offerings.

Orthofix Announces Exclusive US License for IGEA's Bone and Joint Stimulation Devices

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced that it plans to release financial results for the first quarter 2021 before market open on Friday, April 30, 2021. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may access

Orthofix Schedules First Quarter Earnings Release and Conference Call for April 30, 2021

ConforMIS

Integra LifeSciences Holdings

SeaSpine Holdings

Zimmer Biomet Hlds

Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix announces the FDA 510(k) clearance and first patient implant of the FORZA™ Ti TLIF Spacer System with Nanovate Technology.

Orthofix Announces FDA Clearance and First Patient Implant of the 3D-Printed FORZA Titanium TLIF Spacer System with Nanovate Technology

Medtronic

Stratasys

These 3D stocks have proven to be instrumental in improving the quality of healthcare outcomes The post 3 3D Stocks That Can Advance the World of Healthcare appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn't matter if you have $500 in savings or $5 million.

3 3D Stocks That Can Advance the World of Healthcare

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Announces Board Chair Transition; Catherine Burzik nominated for election as the next Chair of the Company's Board of Directors.

Orthofix Announces Board Chair Transition

Orthofix's (OFIX) CONSTRUX Mini Ti Spacer System, designed with nanoscale surface is the first 3D-printed titanium interbody, was launched to enhance ACDF procedures.

Orthofix (OFIX) Wins FDA Clearance for CONSTRUX Mini Ti System

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix launches the Company's first 3D-printed titanium cervical interbody, the CONSTRUX™ Mini Ti Cervical Spacer System with Nanovate™ Technology.

Orthofix Announces FDA Clearance and Initial Patient Implant of the Company's First 3D-Printed Titanium Cervical Spacer System with Nanovate Technology

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix launches recycling initiative for its bone growth therapy devices, becoming the first and only company in the U.S. to offer such a program.

Orthofix Launches Nationwide Recycling Program to Improve Sustainability

Orthofix (OFIX) registers improvement in Global Spine segment's revenues during Q4 due to strength in its spinal implants portfolio.

Orthofix's (OFIX) Q4 Earnings Top Estimates, Margin Declines

Orthofix Medical Inc. (OFIX) CEO Jon Serbousek on Q4 2020 Results - Earnings Call Transcript

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2020. Net sales for the fourth quarter were $117.6 million, earnings (loss) per share (“EPS”) was $(0.48) and adjusted EPS was $0.44. For fiscal year 2020, net sales were $406.6 million, EPS was $0.13 and adjusted EPS was $0.26. “We were very pleased with our performance during the fourth quarter both from a financial and operatin

Orthofix Reports Fourth Quarter and Fiscal Year 2020 Results

With FITBONE, Orthofix (OFIX) claims itself to be the only orthopedic company that offers a comprehensive portfolio of both internal and external fixation solutions for limb reconstruction.

Orthofix (OFIX) Launches Limb Lengthening System in US & UK

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference, Friday, February 19, 2021 at 9:30 a.m. ET. The conference will be held in a virtual meeting format, and one-on-one

Orthofix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference on February 19

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced that it plans to release financial results for the fourth quarter and full year 2020 before market open on Friday, February 26, 2021. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested p

Orthofix Schedules Fourth Quarter and Full Year Earnings Release and Conference Call for February 26, 2021

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited fourth quarter 2020 net sales of approximately $118 million, a decrease of 3% on a reported basis and 4% on a constant currency basis. For the full year 2020, preliminary unaudited net sales were approximately $407 million, a decrease of 12% on both a reported and constant currency basis. On a sequential basis, compared to the third quarter of 2020, net sales increased 6%. “First I woul

Orthofix Announces Preliminary 2020 Fourth Quarter and Full Year Net Sales Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in two upcoming virtual investor conferences. J.P. Morgan Healthcare Conference The Company will be presenting on Thursday, January 14, 2021 at 2:00pm ET. ICR Westwicke Conference 2021 The Company will be presenting on Thursday, January 14, 2021 at 4:00pm ET. Both presentations will be webcast live

Orthofix Announces Participation in Upcoming J.P. Morgan Healthcare and ICR Westwicke Conferences

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek will participate in a fireside chat during the Stifel 2020 Virtual Healthcare Conference, Monday, November 16, 2020 at 10:40 a.m. ET. The conference will be held in a virtual meeting format, and one-on-one meetings will be held before and immediately following the fireside chat. A live audio webcast will be available on the Company's website at ir.orth

Orthofix to Present at the Stifel 2020 Virtual Healthcare Conference on November 16

Orthofix Medical Inc. (OFIX) CEO Jon Serbousek on Q3 2020 Results - Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of 247.62% and 29.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Orthofix International Stock (OFIX)